The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Pfizer has launched its Vaccines Division’s Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific...
Merck KGaA is investing EUR 250 million ($275 million) over the 2019-2022 period in a new Biotech Development Center for biopharmaceutical development and manufacturing for new biological entities in clinical studies in Corsier-sur-Vevey,...
As part of the ongoing regulatory approval process for AbbVie’s pending $63-billion acquisition of Allergan, Allergan has agreed to divest three drugs: one investigational drug to AstraZeneca and two commercial products to Nestlé. AbbVie has also...
AstraZeneca plans to invest $1 billion under a strategy to achieve zero-carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon-negative by 2030.
Launched this week at the World Economic Forum (WEF)...
Piramal has agreed to sell its healthcare data and analytics unit, Decision Resources Group (DRG), to Clarivate Analytics for $950 million (includes $900 million on closing and $50 million to be received at the end of 12 months from the date of...
Merck & Co. has completed its previously announced $2.7-billion acquisition of ArQule, a biopharmaceutical company focused on the discovery and development of kinase inhibitors for treating cancer and other diseases. With the completion of the...
Eli Lilly and Company reports that it will invest more than $470 million to build a new parenteral (injectable) product and delivery device manufacturing facility in North Carolina’s Research Triangle Park.
The new manufacturing...
Civica Rx, a pharmaceutical company providing drugs in shortage, has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications of Civica-owned abbreviated new drug applications.
This partnership has an...
AstraZeneca is investing more than $500 million over five years in France in several manufacturing and research and development (R&D) projects, including a $230-million investment to expand its manufacturing site in Dunkirk, France.
The...
Astellas has completed its $3-billion acquisition of Audentes Therapeutics, a San Francisco, California-based adeno-associated virus (AAV) clinical-stage gene-therapy company that focuses on rare neuromuscular diseases.
With the completion of the...
AbbVie, upon completing its $63-billion acquisition of Allergan, plans to create a new global business, Allergan Aesthetics, which will include Allergan’s Botox and related products. The new business will become effective upon the expected...
Biogen has agreed to acquire from Pfizer a clinical-stage small-molecule drug for treating neurological diseases in a deal worth up to $710 million ($75 million upfront and $635 million in potential milestones).
The drug, a central nervous system...
A roundup of developments and latest news from Germany (Bayer, WuXi Biologics), South Korea (Avacta, Daewoong), and US (Hikma, ANI Pharmaceuticals).
Germany
Bayer, WuXi Biologics in Acquisition Agreement for Bayer’s Drug-Product Mfg Plant
Bayer...
California’s Governor Gavin Newsom has proposed a new CalRx generic-drug program in his 2020–21 State Budget proposal that he submitted to California’s State Legislature, which would make California the first state to create its own generic-drug...
The European Medicines Agency (EMA) and its European and international partners have launched a pilot program to increase their cooperation in the inspection of manufacturers of sterile medicines for human use. This new initiative is built on...
